tbuckley/cabot-search huggingface dataset:
Table of Contents
Authors: Francesco Nardo, Fabrizio Casagrande, Massimo Boemi, Paolo Fumelli, Pierpaolo Morosini, Roberto Burattini, Seiichiro Kano, Masako Doi, Arshag Mooradian, Michael Haas, Khuram Wadud, Elisabet Agardh, Carin Gustavsson, Marie Nilsson, Carl-David Agardh, Steen Haugaard, Ove Andersen, Steen Pedersen, Flemming Dela, Mogens Fenger, Bjørn Richelsen, Sten Madsbad, Johan Iversen, Eun-Jung Rhee, Young-Choon Kim, Won-Young Lee, Chan-Hee Jung, Ki-Chul Sung, Seung-Ho Ryu, Ki-Won Oh, Sun-Woo Kim, Carl Behre, Gerhard Brohall, Johannes Hulthe, Björn Fagerberg
Journal: Metabolism (2006)
SYMPOSIUM ON INSECTS AND DISEASE
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Summer tuberculosis
Authors: M C KELSEY, C A MITCHELL, M GRIFFIN, A M EMMERSON
Journal: Thorax (1999)

Neurofibromatosis has been known to involve blood vessels throughout the body.Pulmonary involvement with interstitial fibrosing alveolitis has been described but no case of pulmonary vascular involvement has been reported to date.A 51 year old patient with cutaneous neurofibromatosis is described who presented with severe pulmonary hypertension and radiographic, scintigraphic, and angiographic evidence of chronic thromboembolic pulmonary hypertension.Severe intimal fibrosis consistent with vascular involvement with neurofibromatosis was found on endarterectomy with no evidence of pulmonary thromboembolism.Neurofibromatosis of pulmonary arteries should be considered as a possible cause of pulmonary hypertension.
Poisoning—General Treatment and Prevention
Authors: Jay M. Arena
Journal: JAMA (1975)

PARTS I and II (232:1272, 1975; 233:358, 1975) of this article concerned various ways of treating poisoning. This section will deal with complications of treatment and with prevention of poisoning. <h3>Complications</h3><h3>Acidosis.—</h3> The acidosis that occurs in poisoning may be due to either (1) loss of base with reduction in plasma pH and carbon dioxide combining power, which may be caused by vomiting and diarrhea, and (2) increase in acid with reduction of pH by three methods: (<i>a</i>) metabolism of a poison to an acid intermediate (such as methanol to formic acid), (<i>b</i>) retention of carbonic acid during respiratory depression, and (<i>c</i>) retention of metabolic acids during anuria from renal damage. The prompt administration of polyionic solutions containing glucose will often prevent the development of severe acidosis, which may occur in the course of poisoning with salicylates, methyl alcohol, phenol, formaldehyde solutions, and polymeric phosphates for example. If severe metabolic
Population Study of Hearing Disorders in Adults: Preliminary Communication
Journal: Journal of the Royal Society of Medicine (1981)

The Institute of Hearing Research is embarked upon a study of the prevalence, characteristics and determinants of hearing problems and tinnitus in the adult population of the UK. One of its objectives is to ascertain the size of the problem in terms both of numbers of people affected and the degrees to which they are affected. Such knowledge is highly relevant to any consideration of the services needed for the adult hearing impaired. The overall plan for the study and the results of its pilot study are outlined. In Tier A, a questionnaire on hearing difficulties and tinnitus was sent to 6804 persons living in Cardiff, Glasgow, Nottingham and Southampton. This enabled stratification of respondents by age groups and reported impairments, and thereby permitted appropriate sampling ratios from those strata to be invited to attend the clinics for the Tier B clinical and audiological investigations. Response rates were around 80% at Tier A and 50% at Tier B; domiciliary follow up showed the biases in non-responders and non-attenders to be minimal. About 25% of the sample reported some hearing difficulty, and about 17% reported an experience of tinnitus that was more than transitory or temporary noise-induced. Taking a criterion of over 25 dB hearing level in the better ear, averaged across 0.5, 1, 2 and 4 kHz, a prevalence estimate for the UK population is that 19.9 +/- 4.4% of adults are so affected. About 0.5-1% of adults appear to be severely affected by tinnitus; this amounts to about 200 000 persons in the UK. The scale of the problem has not been fully appreciated before and points to an urgent need to develop further the clinical services and research effort in the field of tinnitus.
Aldose reductase in diabetic cataracts
Authors: J. H. Kinoshita
Journal: JAMA (1981)

AN ASSOCIATION between cataracts and diabetes in humans has been suspected for about two centuries. This in turn has resulted in considerable laboratory research in the development of animal models in which the eye disease process could be studied in detail. From these studies, it was observed that diabetes produced either by pancreatomy or by chemical destruction of beta cells of the pancreas leads to cataracts in dogs, rats, rabbits, monkeys, and other animals. Moreover, the rapidity of cataract development paralleled the severity of the diabetes.<sup>1</sup>Thus, this diabetic complication appears directly related to the glucose level. The cataractous process, first appearing as vacuoles in the equatorial region, proceeds to opacification of the lens nucleus and finally the entire lens (Fig 1). An understanding of the mechanism involved in the development of diabetic cataracts was greatly accelerated by the fact that the process could be duplicated in rats fed
Inadequate orchiectomy for patients with testicular tumors
Authors: C. Markland
Journal: JAMA (1973)

Nineteen of 36 patients with nonseminomatous germinal tumors had inadequate primary surgical management due to local biopsy or surgical orchiectomy. Treatment of these patients by hemiscrotectomy and inguinal lymphadenectomy showed residual or recurrent tumor in six, two patients now being tumor-free. High inguinal orchiectomy is the recommended surgical technique for all unknown scrotal masses, as it lessens the chance of inadequate removal of a testis tumor.
Improved event free survival (EFS) with the novel retinoid, bexarotene (BEX) and gemcitabine/carboplatin (G/C) in non-small cell lung cancer (NSCLC)
Authors: M. J. Edelman, J. Kendall, R. Smith, P. F. Hausner, K. Kalra, L. A. Doyle, L. Thomas
Journal: Journal of Clinical Oncology (2004)

7104 Background: BEX (Targretin) is a novel retinoid targeting the RXR receptor. RXR expression has been correlated with survival in NSCLC. Phase I/II data have indicated prolonged survival in NSCLC when BEX was added to cisplatin/vinorelbine. We sought to determine whether BEX could improve outcome in patients (pts) with advanced NSCLC when added to C/G. Methods: Pts with stage IIIb (pleural effusion) or stage IV (including brain metastases) NSCLC, PS 0–2 and nl organ function were eligible. Treatment consisted of BEX 400 mg/m2 po daily with C AUC = 5 d1, G 1000 mg/m2 d1,8 for six cycles. BEX was continued after C/G until progression. atorvastatin 10 mg qd was required to prevent hypertriglyceridemia (TG) and titrated. Outcomes were compared with historical controls (n=33) from pts entered on recent prospective trials with similar entry criteria and treated with modern platinum based therapy at our institution. Results: 43 pts were entered. All pts received at least the first dose of therapy and are included in the analysis for survival, 41 are evaluable for toxicity and 38 for response. There were 29 M/14F, PS 0/1/2 = 15/26/2, 31 Caucasian/ 11 AA/ 1 other. Stage: 12 IIIb/ 31 IV. 23% of pts had brain metastases, 35% had weight loss. Median cycles= 5 (range 1–9). Toxicity: Grade III/IV TG in 18/41 pts but there were no episodes of pancreatitis. 19/41 pts experienced grade III/IV neutropenia, but only 3 febrile episodes. 18/41 pts had grade III/IV thrombocytopenia, but only one bleeding episode (epistaxis). Overall response rate was 21% ( 1 CR /7 PR/ 23 SD/ 7 PD/ 1NE/ 4 too early). 56% of BEX treated pts were free from progression at 6 month vs. 27%of controls (p=.03). Median EFS was 7.3 mo. vs. 3.9 mo for controls (p=.11). 1 year survival is 10.9 mo vs. 9.2 mo. for controls (p= n.s.). Conclusions: This initial analysis appears to support the benefit of BEX added to G/C in terms of EFS. TG is a major problem and led to frequent BEX interruptions which may have compromised the potential efficacy of BEX. Starting atorvastatin dose was increased to 40mg midway through the study. These promising findings will require confirmation in Phase III studies. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ligand Ligand Ligand; Lilly Oncology
Classified Advertising
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Management of cancer
Authors: W. R. Barclay
Journal: JAMA (1976)

Cancer is viewed by the public and the federal government as a major health problem, deserving of large expenditures of public and private funds. However, the public holds a somewhat simplistic view of the problem, perceiving it as a single disease awaiting the discovery of a single cure that can be found if a sufficiently large sum of money is spent on the search. Actually, of course, the term "cancer" encompasses many diseases with different etiologies and widely varying clinical courses. The treatment of cancer involves a wide variety of approaches, and a single curative agent is not in prospect. The medical profession views cancer as a major challenge, fully appreciates the complexity of the problem, and devotes major efforts to research, diagnostic studies, and treatment methods.The Journalattempts to keep physicians abreast of current developments in the field of cancer with a regular feature, "Topics in Oncology," and
VENOMOUS ANIMALS
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical Genetics
Authors: David Yi-Yung Hsia
Journal: New England Journal of Medicine (1960)

Disturbances in Carbohydrate MetabolismImprovements in biochemical technic have required a revision in the theories regarding at least two of the disturbances in carbohydrate metabolism. Fructosuria is a rare error of metabolism characterized by a congenital inability to utilize fructose completely. The condition is perfectly benign, and important only in the differential diagnosis of diabetes mellitus. In 1957 Froesch and his co-workers97 reported on a disorder of fructose metabolism differing from essential fructosuria by its marked intolerance to fructose. The condition was present in 7 members of a large family and appeared to be transmitted by an autosomal recessive gene. . . .
Medicolegal
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Valve Replacement for Aortic Stenosis in Patients With Poor Left Ventricular Function
Authors: Julian Collinson, Michael Henein, Marcus Flather, John R. Pepper, Derek G. Gibson
Journal: Circulation (1999)

Background —Long-standing aortic stenosis causes significant left ventricular (LV) dysfunction, which may progress irreversibly. In many cases, LV function can be salvaged by aortic valve surgery, although debate exists regarding the best valve prosthesis to use. Methods and Results —We studied 33 patients retrospectively who had significant aortic stenosis and impaired LV systolic function, as assessed by transthoracic Doppler echocardiography. Patients were assessed preoperatively and before discharge from the hospital. A total of 20 patients received a stentless (homograft or Toronto) valve, and 13, a stented valve. No patient had significant aortic regurgitation or other valvular disease. Preoperatively, fractional shortening was 18.8±5.5% in the stentless group and 18.6±3.8% in the stented group. Postoperatively, it was 25.6±6.9% ( P &lt;0.001 compared with baseline) and 17.0±2.8%, respectively ( P &lt;0.001 compared with stentless group). Fractional shortening improved because of a reduction in LV end-systolic and end-diastolic dimensions in the stentless group. Systolic long axis function at the LV free wall also recovered, with an increase in systolic excursion and both peak shortening and lengthening rates. No change was noted in mitral valve Doppler patterns. Conclusions —Patients who received a stentless valve demonstrated a significantly greater early improvement in LV systolic function compared with those who received a stented valve.
Suppression of Alveolar Macrophage Membrane-Receptor-Mediated Phagocytosis by Model Particle-Adsorbate Complexes: Physicochemical Moderators of Uptake
Authors: George J. Jakab, Terence H. Risby, Shelley S. Sehnert, Robert R. Hmieleski, Matthew I. Gilmour
Journal: Environmental Health Perspectives (1990)

In order to assess the abilities of alveolar macrophages (AMs) to phagocytize adsorbent-adsorbate complexes, rat AMs were incubated in vitro with two carbon blacks that have 15-fold differences in specific surface areas (ASTM classification N339 less than Black Pearls 2000) sorbed with 0.5 and 1.0 monolayer coverages of a polar and semi-polar adsorbate (acrolein and benzofuran, respectively). One-half monolayer coverages of N339 with either adsorbates significantly suppressed the phagocytosis of the carbon black, whereas one monolayer coverage did not. Neither adsorbate at either coverages affected the phagocytosis of Black Pearls 2000. The capacity of macrophages to phagocytize a subsequent particle challenge via the Fc-membrane receptor was quantified following treatment of the macrophages with the carbon black-adsorbate complexes. Treatment of the macrophages with carbon black N339-adsorbates complexes at both coverages impaired Fc-receptor-mediated phagocytosis, whereas no effect was observed when the carbon black was Black Pearls 2000. The results of this study indicate that the surface properties of the particles, the chemical properties of the chemical pollutants, and the interactions between particles and pollutants play a major role in defining the biological effect of particle-pollutant complexes.
RAILWAY EMERGENCY SUPPLIES.
Journal: JAMA (1902)

One of the leading railroads in the middle west has initiated a practice that seems eminently proper and likely to be useful. Every freight and passenger train is supplied with an emergency medicine chest and packets and the trainmen are to be instructed in their use. It often happens that medical aid is not immediately available in cases of railroad accidents and if physicians happen to be present they are not always provided with the medicines and appliances that are desirable; hence the utility of first-aid packages and a supply of such drugs, etc., as are useful in cases of accident. The medicine chests for the passenger trains are naturally to be more complete and will contain a considerable variety of articles suitable for emergencies of sudden injury or sickness. On the freight trains the outfits are simpler and are accompanied with directions for their use. It is prescribed that
THE RECOGNITION OF FUNCTIONAL INSUFFICIENCY OF THE KIDNEYS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
J Air Pollut Control Assoc, Pittsburgh
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The quality of survival in response to treatment
Authors: W. B. Patterson
Journal: JAMA (1975)

THE KIND of life a patient lives is as important as the fact that he is living. Physicians seldom argue over this basic premise. The quality of life, after all, is the major reason there is a medical prefession—because pain, anxiety, and other forms of misery are not happily tolerated by mankind. Recently, as we have learned to use more aggressive therapy and to continue it with life-sustaining ancillary aids, criticism has been raised that aggressive treatment often ignores patient welfare in the interest of science. The criticism is that therapy that prolongs life at a great cost in suffering, hospitalization, and money is a failure, not a success. Therefore, it is essential that we grapple with a criterion of response to therapy that deals with quality of life, knowing in advance that such criteria do not lend themselves easily to measurement and that we will presumably end up with